Figures & data
Abbreviations: COPD, chronic obstructive pulmonary disease; FDCs, fixed-dose combinations; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; PK, pharmacokinetic; RCT, randomized controlled trial; SAEs, serious adverse events.
Note: Overall analysis performed by comparing LABA/LAMA FDCs versus LABAs or LAMAs (A), and subset analysis considering each specific FDC versus monocomponents (B).
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; O, olodaterol; SAEs, serious adverse events; T, tiotropium; U, umeclidinium; V, vilanterol.
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; O, olodaterol; SAEs, serious adverse events; T, tiotropium; U, umeclidinium; V, vilanterol.
Note: Treatments have been plotted on the X-axis according to SUCRA (score of 1 being the safest) and on the Y-axis according to the rank of being the best treatment (score of 1 being the safest).
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDC, fixed-dose combination; G, glycopyrronium; I, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; PCB, placebo; SUCRA, surface under the cumulative ranking curve; T, tiotropium; U, umeclidinium; V, vilanterol.
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDC, fixed-dose combination; G, glycopyrronium; I, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; PCB, placebo; SUCRA, surface under the cumulative ranking curve; T, tiotropium; U, umeclidinium; V, vilanterol.
Note: *P<0.1.
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; OR, odds ratio; SAEs, serious adverse events; SND, standard normal deviate; T, tiotropium; U, umeclidinium; V, vilanterol.
Abbreviations: A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; OR, odds ratio; SAEs, serious adverse events; SND, standard normal deviate; T, tiotropium; U, umeclidinium; V, vilanterol.